Xcout IntelLIPAC Oncology LLC competitors & alternatives
The 12 closest competitors and alternatives to LIPAC Oncology LLC among biotechnology companies — ranked by similarity to what LIPAC Oncology LLC actually does, not by market-cap band.
Subscribe to see LIPAC Oncology LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About LIPAC Oncology LLC
LIPAC Oncology LLC is a clinical-stage oncology company that develops precision targeted, locally delivered taxane technology platforms for localized cancer tumors. Its product pipeline targets medical conditions with high unmet needs, including bladder cancer, malignant pleural effusion, upper tract urothelial carcinoma, ovarian cancer, and intraperitoneal carcinoma.
LIPAC Oncology LLC at a glance
LIPAC Oncology LLC is a biotechnology company headquartered in United States. Its most recent funding round raised $372,500 in January 2020. Xcout tracks 4 named people at LIPAC Oncology LLC, including Ramachandran “TR” Thirucote (chairman & chief EXECUTIVE officer).
LIPAC Oncology LLC leadership
- Ramachandran “TR” Thirucotechairman & chief EXECUTIVE officer
- Michael Oefeleinchief Medical officer
- Charles L. Hooperboard member
- Vincent DeRosaboard member
LIPAC Oncology LLC funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $372,500 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 LIPAC Oncology LLC competitors
Ranked by semantic similarity — how close each company is to LIPAC Oncology LLC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Biotech
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
Similar biotechnology company
Irazu Oncology, LLC is a biotechnology company that develops cancer immunotherapies utilizing bacterial outer membrane vesicles. The company creates off-the-shelf treatments designed to activate anti-tumor immune responses through a scalable manufacturing process, aiming to provide more accessible and affordable therapeutic options for cancer patients.
Similar biotechnology company
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
Similar biotechnology company
PIC Therapeutics, Inc. is a biopharmaceutical company headquartered in Natick, Massachusetts, dedicated to developing life-changing medicines for patients with cancer. The company focuses on oncology research and therapeutic product development.
Similar biotechnology company
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Similar biotechnology company
Haniva Technology LLC is a biotechnology company that develops patented combination therapies and drug delivery devices to treat various forms of cancer. Its research focuses on using non-thermal plasma alongside hypoxia-activated DNA-damaging agents to selectively target and reduce tumor volume, prevent metastasis, and serve as an adjuvant treatment following tumor resection.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Similar biotechnology company
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Similar biotechnology company
Anchiano Therapeutics was a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and innovative treatments for cancer, including non-muscle-invasive bladder cancer. The company completed a merger with Chemomab, leading to the formation of Chemomab Therapeutics Ltd.
Similar biotechnology company
St. James Therapeutics is a clinical-stage biopharmaceutical company that develops specialized topical skincare products to treat chemotherapy-induced side effects, specifically hand-foot syndrome. The company serves cancer patients by creating science-backed solutions designed to make cancer treatment more tolerable.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of LIPAC Oncology LLC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for LIPAC Oncology LLCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →